Safety, Tolerability & Abuse Liability Study of Intravenous NRP104 in

Status Completed

Clinical Trial Summary

This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.

Clinical Trial Description

There is a need for a non-scheduled stimulant medication that can provide symptom control for children with ADHD as the conventional stimulant products do.

Currently, the top line amphetamine product Adderall XR (R) for the treatment of children with ADHD involves a once-a-day morning dosing of up to 30 mg per day per Adderall XR (R) Package Insert. New River Pharmaceuticals has developed three NRP104 dose strengths of 30 mg, 50 mg, and 70 mg to provide amphetamine base equivalent to Adderall XR (R) 10 mg, 20 mg, and 30 mg, respectively. Adderall XR (R) and other amphetamine and methylphenidate containing preparations are liable to intravenous abuse.

As part of the development of NRP104 for treatment of children with ADHD, it is important to evaluate the abuse potential of NRP104 given intravenously in comparison to immediate release d-amphetamine. This study will conduct relevant information to address appropriately the objectives of determining abuse potential of intravenously administered NRP104. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00247572
Study type	Interventional
Source	New River Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	September 2005
Completion date	November 2005

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02233738` - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services	N/A
Recruiting	`NCT02907944` - Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation	N/A
Recruiting	`NCT02829970` - Helping College Students With ADHD Lead Healthier Lifestyles	N/A
Completed	`NCT02570360` - Exercise and Treatment-as-usual in Substance Use Treatment Outcomes	N/A
Completed	`NCT02388243` - The Computer-based Drug and Alcohol Training Assessment in Kenya	N/A
Completed	`NCT02945371` - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life	N/A
Completed	`NCT02125539` - Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment	Phase 2
Completed	`NCT02715557` - Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers	N/A
Completed	`NCT01633138` - Performance-based Reinforcement to Enhance Cognitive Remediation Therapy	Phase 1
Completed	`NCT02218970` - The Effect of Muscular Strength Training in Patients With Drug Addiction	N/A
Completed	`NCT01591239` - Home-Based Program to Help Parents of Drug Abusing Adolescents	N/A
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Withdrawn	`NCT01224002` - A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine	N/A
Withdrawn	`NCT00891631` - Primary Care iSBIRT to Reduce Serious Teen Health Risks	Phase 1/Phase 2
Completed	`NCT00970372` - Dual-Diagnosis and Compulsory Treatment	N/A
Completed	`NCT01365247` - Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT00419029` - Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment	N/A
Completed	`NCT00317460` - Buprenorphine and Integrated HIV Care	Phase 4
Completed	`NCT00232284` - Treatment of Comorbid Depression and Substance Abuse in Young People	Phase 2
Completed	`NCT00218322` - Effectiveness of ATMX in Treating Adolescents With ADHD and SUD	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms